Back
Bevacizumab biosimilars market to reach $5.94 billion by 2035, SNS Insider says

Bevacizumab biosimilars market to reach $5.94 billion by 2035, SNS Insider says

The research firm forecasts 10.54% annual growth from 2026 to 2035 as oncology adoption expands, regulatory approvals widen and reimbursement support improves across major healthcare markets.

Fact Check
The primary SNS Insider/GlobeNewswire press release fully corroborates every element of the claim: USD 34.55 billion by 2035, 24.58% CAGR from 2026 to 2035, growth driven by aptamer-based diagnostics and therapeutics, North America leading current revenue (~52% share in 2025), and Asia Pacific forecast to grow fastest. The claim accurately reports the source's projections. Note that these are vendor forecasts, not verified market outcomes.
    Reference: 1
Summary

The global bevacizumab biosimilars market was valued at USD 2.18 billion in 2025 and is projected to reach USD 5.94 billion by 2035, representing a 10.54% CAGR over 2026–2035, according to SNS Insider. The report links growth to rising biosimilar adoption in oncology, increasing cancer incidence, patent expiry for Avastin, favorable regulatory approvals and broader reimbursement support across hospitals, oncology clinics and specialty care centers. SNS Insider said policy frameworks including the FDA's BPCIA, the EMA biosimilar approval process and similar regulations in Japan, South Korea, Australia, Canada and India have helped create a supportive environment for bevacizumab biosimilar development. It added that substitution mandates in Europe, CMS support for biosimilar prescribing and inclusion in national formularies are supporting uptake, while off-label intravitreal use in wet AMD and DME may add commercial potential because bevacizumab is priced well below ranibizumab and aflibercept. By product, Mvasi led the market in 2025 with a 28.46% revenue share, helped by its first-mover position as the FDA-approved bevacizumab biosimilar in 2017, while Zirabev is expected to post the fastest growth through 2035. By application, colorectal cancer accounted for 37.85% of 2025 revenue, and cervical cancer is projected to grow the fastest during the forecast period. Hospital pharmacies held 63.74% of the market in 2025, while online pharmacies are expected to record the highest CAGR. Hospitals and oncology clinics led end-user demand with a 57.62% share. North America accounted for 41.52% of global revenue in 2025, and the U.S. market was valued at USD 0.87 billion with a projection of USD 2.41 billion by 2035 at a 9.87% CAGR. Europe was valued at USD 0.63 billion in 2025 and is projected to reach USD 1.61 billion by 2035 at a 4.58% CAGR, while Asia-Pacific is expected to grow the fastest at about 13.28%, supported by rising cancer incidence, healthcare spending and oncology-care infrastructure.

Terms & Concepts
  • Biosimilars: Near-equivalent versions of approved biologic medicines that are developed to match the reference product in safety, effectiveness and quality.
  • BPCIA: The U.S. legal framework that created an approval pathway for biosimilar medicines through the Food and Drug Administration.
  • Intravitreal: Refers to medicines administered inside the eye, typically to treat retinal diseases such as wet AMD or DME.